EHA 2019 | First-line therapies for CLL
In this video, Arnon Kater, PhD, of University of Amsterdam, Amsterdam, Netherlands, talks about first-line therapies for chronic lymphocytic leukemia (CLL). Prof. Kater was speaking at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.
Transcript (edited for clarity)
There are a lot of trials now, for first-line CLL, actually showing that these novel agents actually do have a place. So, I think a very important study that probably will be important, not next year, but the year after that, is the study that we do together with the German group, and the Nordic group, the GAIA
There are a lot of trials now, for first-line CLL, actually showing that these novel agents actually do have a place. So, I think a very important study that probably will be important, not next year, but the year after that, is the study that we do together with the German group, and the Nordic group, the GAIA CLL-13 trial, where we compare venetoclax–obinutuzumab, venetoclax–rituximab, and the triple combination, that’s an important one. Also, what we heard this weekend from the German’s venetoclax–obinutuzumab trial, which actually, is both, if you compared that to the MURANO trial, it’s both obinutuzumab and rituximab. So that’s different, but also it’s first-line versus relapsed, but at least you see very high MRD negative rates, so, undetectable MRD rates. And you also see now, 50% of complete responses. So, I think it’s a very powerful combination, on one side, and the other side, there is still space to improve on this even further.
Read more...
